Author: Keith Ashcroft - Page 2

How to Use Patient Assistance Programs When No Generic Medication Exists

Keith Ashcroft
|
January 10
|
13

When no generic drug exists, patient assistance programs can cut costs from thousands to zero. Learn how to apply, avoid common traps like accumulator adjustments, and find help for brand-name medications.

Population Pharmacokinetics: How Data Proves Drug Equivalence

Keith Ashcroft
|
January 9
|
0

Population pharmacokinetics uses real-world patient data to prove drug equivalence, especially for vulnerable populations. Learn how it's replacing traditional bioequivalence studies and gaining global regulatory approval.

Immunosuppressive Combinations: Generic Options for Transplant Care

Keith Ashcroft
|
January 7
|
13

Generic immunosuppressants like tacrolimus and mycophenolate offer the same protection as brand-name drugs at 80% lower cost. Learn how they work, their risks, and why they’re now the standard for transplant care.

How to Use Pharmacy Apps to Track Potential Drug Interactions

Keith Ashcroft
|
January 5
|
12

Learn how to use pharmacy apps to spot dangerous drug interactions before they happen. Discover the best apps for patients and pros, how they work, and how to avoid costly mistakes with prescriptions, supplements, and OTC meds.

Muscle Aches from Statins: What Really Causes It and What to Do

Keith Ashcroft
|
January 4
|
15

Muscle aches from statins are common but often overestimated. Learn what's really causing the pain, when to worry, and how to stay protected without quitting your heart medication.

Annual Boxed Warnings Summary: What Changed and Why It Matters

Keith Ashcroft
|
January 1
|
0

The 2025 FDA boxed warnings update reveals new, specific safety alerts for drugs like GLP-1 agonists and immunomodulators. These changes mean clearer guidance for doctors and safer use for patients.

Monitoring During Immunosuppressive Therapy: Essential Lab Tests and Imaging for Safety and Effectiveness

Keith Ashcroft
|
December 29
|
13

Essential lab tests and imaging for patients on immunosuppressive therapy to prevent rejection, toxicity, and infection. Learn how drug levels, TTV monitoring, and routine blood work keep you safe long-term.

PTSD Nightmares: How Prazosin and Sleep Therapies Actually Work

Keith Ashcroft
|
December 27
|
14

PTSD nightmares are more than bad dreams-they're a neurological symptom that disrupts recovery. Learn how prazosin, CBT-I, and imagery rehearsal therapy work, what the research says, and which approach is right for you.

FDA Listing for Biosimilars: How They Are Evaluated and Approved

Keith Ashcroft
|
December 25
|
8

The FDA doesn't rate biosimilars like generics - it rigorously evaluates them for molecular similarity, safety, and efficacy. Learn how the approval process works, why only 17 are interchangeable, and how they're changing patient access to biologics.

When to Recommend Authorized Generics: Pharmacist’s Practical Guide

Keith Ashcroft
|
December 19
|
9

Pharmacists should recommend authorized generics for patients with allergies, narrow therapeutic index drugs, or modified-release formulations. Learn when and why to suggest them over regular generics.